Article
Pfizer, Glaxo, J&J Grab ASCO Spotlight
New drugs that target genetic weakness in cancer in the spotlight as ASCO previews its closely followed conference.
06:01PM 05/16/12
Article
ASCO '12 Abstract Dump: Cancer Stocks in Focus
Array Biopharma, Exelixis, Aveo and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.
06:00PM 05/16/12
Article
Hot Biotech Stocks Traded by Hedge Funds in First Quarter
A closer look at 13F regulatory filings in the biotech sector for the first quarter.
07:10AM 05/16/12
Article
Mulling Arena Pharma's Future With Obesity Drug on Approval Path
Thoughts and questions following last week's positive FDA panel for Arena's weight-loss drug lorcaserin.
03:09PM 05/14/12
Article
A Health Care Fortnight for the Record Books
Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.
07:00AM 05/14/12
Article
Stocks to Watch: JPMorgan, Arena (Update 1)
JPMorgan Chase discloses a $2 billion loss from trading in its synthetic credit portfolio.
07:35AM 05/11/12
Article
These stocks slump to 52-week lows on Thursday.
01:55PM 05/10/12
Article
Arena Pharma: FDA Panel Live Blog
Join TheStreet biotech columnist Adam Feuerstein as he provides live coverage of the FDA advisory panel reviewing Arena Pharma's obesity drug lorcaserin.
07:43AM 05/10/12
Video
IPO Desktop President Francis Gaskins advises investors to take a pass on LINC Logistics, New Source Energy and Rib-X Pharmaceuticals.
05:30AM 05/10/12
Article
Glaxo's Bid for Human Genome Turns Hostile: Hot Trends
GlaxoSmithKline goes straight to shareholders with a $13-a-share offer.
08:48AM 05/09/12
Article
FDA's Review of Arena Pharma's Obesity Drug Sunnier Than Expected
FDA experts will vote Thursday on whether to recommend approval of Arena's lorcaserin for weight loss.
12:10PM 05/08/12
Article
Vertex Is the Next Gilead Sciences or Alexion
With its cystic fibrosis drug business flourishing, making the case for Vertex to be worth even more is easy.
04:06PM 05/07/12
Article
As Hostile Takeover Bids Recede, Investors Bet on Earnings
A muted reaction to the failure of recent hostile bids may be a signal of long-term earnings confidence from investors.
01:24PM 05/07/12
Article
Top 5 Small-Cap Stocks to Consider Buying
Hecla Mining and Wendy's are among the small-cap stocks investors should consider purchasing in the near term.
11:31AM 05/07/12
Article
Vertex: Two-Drug Cystic Fibrosis Therapy Improves Lung Function
Vertex plans to start a phase III study soon; if approved, the two-drug therapy could treat half of cystic fibrosis patients worldwide.
09:57AM 05/07/12
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Connect with TheStreet